Swiftpharma

Genk ·KBO/BCE: BE 0781.598.284

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	27-04-2026	95 d early	2026-00088559
31-12-2024	31-07-2025	17-06-2025	44 d early	2025-00144381
31-12-2023	31-07-2024	25-07-2024	6 d early	2024-00280885

Metric	This company	Sector median	Position in the sector
Solvency	17.0%	35.1%	better than 30% of 335 sector peers
Net result	€-1.75M	€42k	better than 5% of 335 sector peers
Equity	€835k	€278k	better than 71% of 335 sector peers
Gross operating margin	€-22k	€240k	better than 7% of 334 sector peers
Staff costs	€1.19M	€172k	higher than 92% of 212 sector peers

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€4.90M
Fixed assets	21/28	€4.18M
Intangible fixed assets	21	€2.02M
Tangible fixed assets	22/27	€2.13M
Financial fixed assets	28	€30k
Current assets	29/58	€718k
Amounts receivable within one year	40/41	€255k
Cash & bank	54/58	€434k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€4.90M
Equity	10/15	€835k
Contributions / capital	10/11	€4.41M
Reserves	13	€57k
Accumulated profits (losses)	14	€-3.63M
Amounts payable	17/49	€4.06M
Amounts payable after one year	17	€3.52M
Amounts payable within one year	42/48	€543k
Trade debts payable within one year	44	€372k
Income statement
Gross operating margin	9900	€-22k
Operating result	9901	€-1.67M
Financial income	75	€4k
Financial charges	65	€87k
Result before taxes	9903	€-1.75M
Income taxes	67/77	€998
Net result for the period	9904	€-1.75M
Result to be appropriated	9905	€-1.75M

Summary

NACE primary	Groothandel in farmaceutische en medische artikelen(46460)
Legal form	Private limited company(610)
Incorporation	04-02-2022
Status	Active
Postal code	3600